ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
iShares Health Innovation Active ETF
33.32
0.0000
成交量：
11
成交額：
368.57
市值：
1,332.60萬
市盈率：
- -
高：
33.32
開：
33.32
低：
33.32
收：
33.32
52周最高：
34.86
52周最低：
25.79
股本：
40.00萬
流通股本：
40.00萬
量比：
0.09
換手率：
0.00%
股息：
0.08
股息率：
0.24%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
吉利德與泛美衞生組織就拉丁美洲和加勒比地區艾滋病預防藥物獲取問題達成一致
路透中文
·
昨天
吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性
美股速递
·
昨天
吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平
美股速递
·
昨天
吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市
美股速递
·
昨天
實時行情-紐約之秋：製造業擴張放緩，投入成本創數年新高——紐約聯儲
路透中文
·
昨天
實時行情-受油價和債券收益率飆升影響，美國股市指數回落
路透中文
·
昨天
實時行情-受油價和債券收益率飆升影響，美國股市指數回落
路透中文
·
昨天
市場消息：美國食品藥品監督管理局啓動加速新藥臨床試驗申請試點項目，開始受理相關申請。
智通财经
·
昨天
石藥創新：SYS6010再獲突破性治療認定 III期臨床試驗正在開展
同花顺
·
昨天
恒瑞醫藥：子公司「注射用瑞卡西單抗」獲批開展III期臨床試驗
财中社
·
昨天
可以多活8.2個月！國產雙抗挑戰全球腫瘤「藥王」總生存期勝出
第一财经
·
昨天
恒瑞醫藥(600276.SH)：HRS-4139片獲得藥物臨床試驗批准通知書
智通财经
·
昨天
恒瑞醫藥：子公司HRS-4139片獲臨床試驗批准
智通财经
·
昨天
恒瑞醫藥：瑞卡西單抗獲批開展III期臨床試驗
智通财经
·
昨天
維康藥業(300878.SZ)：黃甲軟肝顆粒獲批開展用於慢性乙型病毒性肝炎肝纖維化的III期臨床試驗
智通财经
·
昨天
維康藥業：黃甲軟肝顆粒獲III期臨床試驗補充申請批准
智通财经
·
昨天
興齊眼藥(300573.SZ)：SQ-25012注射液獲得臨床試驗批准通知書
智通财经
·
昨天
興齊眼藥：SQ-25012注射液獲臨床試驗批准通知書
智通财经
·
昨天
港股異動 | 海西新藥(02637)升逾3% 近期已遞交HX9428的DME IIa期新藥臨床試驗申請
智通财经
·
昨天
強生：瑞布侖特法斯普羅聯合拉茲克魯澤治療一年，因治療相關事件停藥率不足1%
美股速递
·
昨天
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/BMED/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.315,"timestamp":1789565996832,"preClose":33.315,"halted":0,"volume":11,"delay":0,"changeRate":0,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-16 10:12:10 EDT","open":33.315,"high":33.315,"low":33.315,"amount":368.57183,"amplitude":0,"askPrice":33.47,"askSize":1000,"bidPrice":33.39,"bidSize":1000,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":33.315,"sharesOutstanding":360000,"nav":33.210436,"aum":13284174.4,"dividendRate":0.002392,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.23,"preClose":33.315,"latestTime":"16:10 EDT","volume":6,"amount":199.89,"timestamp":1789503006991,"change":-0.085,"changeRate":-0.002551,"amplitude":0},"volumeRatio":0.08501,"impliedVol":0.0634,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.08501,"shares":400000,"dividePrice":0.0797,"high":33.315,"amplitude":0,"preClose":33.315,"low":33.315,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.315,"eps":0,"divideRate":0.002392,"volume":11,"delay":0,"ttmEps":0,"open":33.315,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":33.0422,"twentyDayClose":32.666,"sixtyDayClose":28.5621},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667062306","title":"吉利德與泛美衞生組織就拉丁美洲和加勒比地區艾滋病預防藥物獲取問題達成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062306","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062306?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485029,"startTime":"0","endTime":"0","summary":"吉利德与泛美卫生组织就拉丁美洲和加勒比地区艾滋病预防药物获取问题达成一致路透9月15日-美国制药公司吉利德科学GILD.O周二表示，已与泛美卫生组织达成协议，将在拉丁美洲和加勒比地区扩大其艾滋病预防药物的可及性，以帮助这些地区遏制新发感染。吉利德公司指出，2010年至2024年间，拉丁美洲和加勒比地区的新发艾滋病毒感染病例增加了13%，并归因于艾滋病毒预防药物使用方面的缺口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T45714A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","BK4568","LU2324357040.USD","MEDI","BK4139","LU0965509010.AUD","LU1057294990.SGD","BK4550","IE00B19Z3B42.SGD","LU0114720955.EUR","LU1585245621.USD","TBXU","LU1066051498.USD","BBH","IE00BKVL7J92.USD","LU0058720904.USD","IE0002270589.USD","IBB","LU1037948897.HKD","LU0859254822.USD","SG9999015945.SGD","LU0122379950.USD","SG9999015952.SGD","LU1934455277.USD","SG9999015978.USD","LU0965509101.SGD","LU2112291526.USD","LU0965509283.SGD","LU0889565916.HKD","LU1934455863.HKD","LU0320765992.SGD","IBBQ","TMED","LU1674673691.USD","BMED","IE00B19Z3581.USD","BK4588","LU1037948541.HKD","LU1839511570.USD","BIB","LU0882574055.USD","LU1066053197.SGD","GILD","BK4532","LU0234570918.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1430594728.SGD","LU0289739699.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159280995","title":"吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159280995?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU2324357040.USD","LU0114720955.EUR","MEDI","SG9999015978.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","GILD","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","LU0289739699.SGD","LU2112291526.USD","BK4566","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IBBQ","LU1037948897.HKD","BK4578","SG9999015986.USD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU2357627491.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","LU0882574055.USD","LU1934455277.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU0122379950.USD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU0889565916.HKD","LU0058720904.USD","LU1674673691.USD","BK4550","LU1061106388.HKD","LU1571399168.USD","BMED","LU1066053197.SGD","IE00B3T34201.USD","IE0002270589.USD","BBH","IE00BKVL7J92.USD","LU1934455863.HKD","BK4585","TBXU","TMED","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0109394709.USD","LU0823416689.USD","LU1057294990.SGD","LU0859254822.USD","SG9999015945.SGD","BK4588","LU1674673428.USD","LU1934455194.USD","IBB","BK4532","LU0965509010.AUD","SG9999015952.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153389014?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","LU0965509283.SGD","IE00B19Z3B42.SGD","IBB","IE00B19Z3581.USD","LU0965509101.SGD","BBH","BK4585","LU1778281490.HKD","BIB","LU1037948897.HKD","SG9999015945.SGD","BK4583","IE00BZ1G4Q59.USD","LU1037948541.HKD","LU1430594728.SGD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1674673428.USD","TBXU","LU2324357040.USD","LU1839511570.USD","LU1934455277.USD","BK4139","BK4568","LU1023059063.AUD","SG9999015986.USD","LU0234570918.USD","BK4588","IE00B3T34201.USD","BK4578","LU1934455194.USD","MEDI","LU2112291526.USD","SG9999015978.USD","SG9999015952.SGD","BMED","LU0122379950.USD","LU0109394709.USD","LU1061106388.HKD","LU1066051498.USD","LU0058720904.USD","LU0861579265.USD","LU2089984988.USD","LU0965508806.USD","TMED","LU1585245621.USD","GILD","IE0002270589.USD","LU0882574055.USD","LU0289739699.SGD","LU0114720955.EUR","BK4532","IE00B7SZLL34.SGD","BK4566","LU2087621335.USD","LU0965509010.AUD","LU1674673691.USD","LU1066053197.SGD","LU0320765992.SGD","LU0889565916.HKD","LU1934455863.HKD","LU0823416689.USD","LU1057294990.SGD","LU2468319806.SGD","LU2357627491.SGD","BK4550","LU1571399168.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131138631?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","LU0058720904.USD","BK4139","BIB","LU0965509283.SGD","TBXU","LU2324357040.USD","BK4550","IE00BSNM7G36.USD","LU0114720955.EUR","LU0234570918.USD","LU0289739699.SGD","LU1571399168.USD","IE00B7SZLL34.SGD","LU1066051498.USD","LU1037948541.HKD","LU0122379950.USD","LU1430594728.SGD","SG9999015986.USD","LU1061106388.HKD","LU0965508806.USD","LU2357627491.SGD","BK4578","BK4566","IE00B19Z3B42.SGD","LU0109394709.USD","LU1585245621.USD","SG9999015978.USD","BBH","LU1674673691.USD","LU1023059063.AUD","LU1066053197.SGD","LU0889565916.HKD","LU1934455277.USD","IE00BKVL7J92.USD","LU2089984988.USD","BK4532","BK4568","LU0320765992.SGD","LU1057294990.SGD","LU0861579265.USD","LU1934455194.USD","IE00B3T34201.USD","LU0823416689.USD","IBB","LU1674673428.USD","LU1934455863.HKD","BK4588","IE00B19Z3581.USD","LU2087621335.USD","LU2112291526.USD","LU2468319806.SGD","SG9999015952.SGD","BMED","IE0002270589.USD","LU1037948897.HKD","IBBQ","LU0882574055.USD","LU0965509010.AUD","SG9999015945.SGD","TMED","BK4585","BK4583","LU1839511570.USD","MEDI","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667623990","title":"實時行情-紐約之秋：製造業擴張放緩，投入成本創數年新高——紐約聯儲","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623990","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667623990?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 22:53","pubTimestamp":1789484014,"startTime":"0","endTime":"0","summary":"实时行情-纽约之秋：制造业扩张放缓，投入成本创数年新高——纽约联储美国主要股指收跌；道指领跌，跌幅约1%可选消费品板块是标普500指数中表现最差的板块；能源板块是唯一上涨的板块欧洲STOXX 600指数下跌约0.4%美元小幅走强；美国原油上涨约2.8%；黄金回落；比特币下跌>4%美国10年期国债收益率触及5.041%，创2007年以来新高，目前约为5.00%9月15日-欢迎来到路透记者为您带来的实时市场报道专区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4S45713M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IYH","LU1674673428.USD","LU0466842654.USD","LU0345770993.USD","LU0882574055.USD","LU2089984988.USD","LU0203347892.USD","LU0053666078.USD","JDOC","FHLC","BMED","LU1043141396.HKD","LU2505996681.GBP","IE00B42XCP33.USD","LU1066053197.SGD","MEDX","IE00BVYPNV92.GBP","LU0072461881.USD","FTXH","GDOC","LU0792757196.USD","XLV","LU1551013342.USD","LU2403377893.USD","TRUH","PJP","LU0210528500.USD","IXJ","BK4588","RXL","LU0320765646.SGD","LU0114720955.EUR","IE00BBT3K403.USD","IE00B3T34201.USD","CTNM","IE00BLSP4452.SGD","VHT","LU2417539215.USD","LU1023059063.AUD","LU1989771016.USD","JNJ","LU1551013425.SGD","IHE","IE00BJT1NW94.SGD","LU1935042991.SGD","LU0511384066.AUD","SGXZ57979304.SGD","LU2750360641.GBP","SGXZ80539844.SGD","LU0820561818.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628768","title":"實時行情-受油價和債券收益率飆升影響，美國股市指數回落","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628768","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667628768?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 22:28","pubTimestamp":1789482483,"startTime":"0","endTime":"0","summary":"实时行情-受油价和债券收益率飙升影响，美国股市指数回落美国主要股指全线走低；道指领跌，跌幅约1%可选消费品板块是标普500指数中表现最弱的板块；能源板块是唯一上涨的板块欧洲STOXX 600指数下跌约0.2%美元小幅走强；美国原油上涨>2%；黄金小幅回落；比特币下跌>3%美国10年期国债收益率一度触及5.041%，创2007年以来新高，目前约为5.01%9月15日-欢迎来到路透记者为您带来的市场实时报导专区。受此影响，康蒂尼姆股价暴跌逾11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T45711Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561818.USD","IE000BZT7R73.USD","LU2236285917.USD","IHE","VHT","IE00BZ1G4Q59.USD","LU2487616109.SGD","MEDX","IXJ","LU0345769128.USD","JDOC","SG9999001176.SGD","LU2505996509.AUD","LU2592432038.USD","LU0203347892.USD","TRUH","FHLC","LU0057025933.USD","LU0795875169.SGD","LU1228905037.USD","LU2471134952.CNY","RXL","IE00BLSP4239.USD","BK4568","PJP","GDOC","BK4592","LU1059921491.USD","IE000F7OJYX1.SGD","LU2112291526.USD","LU1043141396.HKD","CTNM","LU1674673428.USD","LU2896262040.SGD","SG9999002224.SGD","LU2471134523.USD","JNJ","FTXH","LU2456880835.USD","LU1066051811.HKD","BMED","LU0820562030.AUD","IYH","XLV","LU1585245621.USD","LU1145028129.USD","LU1221951129.SGD","LU2417539215.USD","IE00BVYPNV92.GBP","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628763","title":"實時行情-受油價和債券收益率飆升影響，美國股市指數回落","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628763","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667628763?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 22:28","pubTimestamp":1789482483,"startTime":"0","endTime":"0","summary":"实时行情-受油价和债券收益率飙升影响，美国股市指数回落美国主要股指全线走低；道指领跌，跌幅约1%可选消费品板块是标普500指数中表现最弱的板块；能源板块是唯一上涨的板块欧洲STOXX 600指数下跌约0.2%美元小幅走强；美国原油上涨>2%；黄金小幅回落；比特币下跌>3%美国10年期国债收益率一度触及5.041%，创2007年以来新高，目前约为5.01%9月15日-欢迎来到路透记者为您带来的市场实时报道专区。受此影响，康蒂尼姆股价暴跌逾11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4S45711Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2505996509.AUD","JNJ","VHT","BK4568","GDOC","LU1145028129.USD","LU2417539215.USD","LU0203347892.USD","LU2468319806.SGD","LU2487616109.SGD","LU1585245621.USD","FTXH","IXJ","BK4592","RXL","LU2112291526.USD","LU1043141396.HKD","LU2896262040.SGD","LU2456880835.USD","PJP","LU0345769128.USD","IYH","LU0057025933.USD","MEDX","LU2471134523.USD","SG9999001176.SGD","FHLC","CTNM","LU2236285917.USD","XLV","LU0795875169.SGD","IE000F7OJYX1.SGD","LU1228905037.USD","JDOC","IHE","LU1059921491.USD","LU2592432038.USD","LU1066051811.HKD","LU0820562030.AUD","IE000BZT7R73.USD","SG9999002224.SGD","TRUH","IE00BVYPNV92.GBP","LU1221951129.SGD","IE00BLSP4239.USD","LU1674673428.USD","LU0820561818.USD","IE00BZ1G4Q59.USD","BMED","LU2471134952.CNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667362891","title":"市場消息：美國食品藥品監督管理局啓動加速新藥臨床試驗申請試點項目，開始受理相關申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667362891","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667362891?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 22:09","pubTimestamp":1789481392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","PSYK","BMED","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667264193","title":"石藥創新：SYS6010再獲突破性治療認定 III期臨床試驗正在開展","url":"https://stock-news.laohu8.com/highlight/detail?id=2667264193","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667264193?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:08","pubTimestamp":1789470480,"startTime":"0","endTime":"0","summary":"中证智能财讯石药创新(300765)9月15日晚间公告，公司控股子公司石药集团巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IBBJ","BK0226","MDTX","300765","IBBQ","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648964","title":"恒瑞醫藥：子公司「注射用瑞卡西單抗」獲批開展III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648964","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667648964?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:55","pubTimestamp":1789462500,"startTime":"0","endTime":"0","summary":"9月15日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司近日收到国家药品监督管理局核准签发的关于注射用瑞卡西单抗的《药物临床试验批准通知书》，将于近期开展III期临床试验。该药物的适应症为颅内动脉粥样硬化性狭窄的成人患者，以降低卒中复发风险。2026年中期，恒瑞医药实现收入154.56亿元，归母净利润44.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874740380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874740380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0060","BK1191","LU1064131003.USD","LU2328871848.SGD","BMED","LU2580892862.HKD","LU1580142542.USD","LU2289578879.USD","BK0183","LU0405327148.USD","LU2097828557.USD","LU1023057109.AUD","LU0405327494.USD","LU1997245094.SGD","LU2148510915.USD","MDTX","LU2580892789.USD","LU2543165471.USD","BK0012","LU2488822045.USD","LU2097828474.EUR","01276","LU2495084118.USD","LU1255011170.USD","IBBJ","IBBQ","LU1820825898.SGD","LU1655091616.SGD","LU1997245177.USD","LU2097828714.EUR","LU1064130708.USD","BK0188","BK0196","LU1781817850.SGD","LU0359201885.HKD","LU0359201612.USD","LU1997244956.HKD","LU1146622755.USD","LU0359202008.SGD","LU1969619763.USD","PSYK","LU1328615791.USD","LU2097828631.EUR","BK0028","600276","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648612","title":"可以多活8.2個月！國產雙抗挑戰全球腫瘤「藥王」總生存期勝出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648612","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667648612?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:46","pubTimestamp":1789461960,"startTime":"0","endTime":"0","summary":"2026年世界肺癌大会，对于国产创新药而言，不只是“被看见”，更要回答一个硬核的问题：到底能不能让患者活得更久。继翰森制药ADC药物刷新全球小细胞肺癌二线治疗最长总生存期（OS）纪录外，另外一款国产创新药挑战全球肿瘤“药王”总生存期的数据也揭晓了。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874734252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874734252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2461242641.AUD","LU1934455863.HKD","LU1989772923.USD","KURE","LU2023250843.SGD","IE00B4R5TH58.HKD","LU2476274720.SGD","LU0823416689.USD","LU1961090484.USD","SG9999002232.USD","09926","LU0477156953.USD","LU0348783233.USD","SG9999001176.SGD","LU0965508806.USD","LU0348825331.USD","LU2361044865.SGD","LU2399975544.HKD","LU2360032135.SGD","SG9999002224.SGD","BK4533","IE00BBT3K403.USD","LU0289739343.SGD","LU1989771016.USD","LU0208291251.USD","LU1941712348.USD","FHLC","LU0070302665.USD","LU0634319403.HKD","SG9999001440.SGD","LU1032466523.USD","MRK","GDOC","XLV","LU0348735423.USD","VHT","IE00BFTCPJ56.SGD","LU2488822045.USD","LU2778985437.USD","LU1116320901.HKD","IE00BLSP4452.SGD","BK4559","LU0098860793.USD","LU0122379950.USD","LU1023059063.AUD","PPH","LU1116320737.USD","LU0472753341.HKD","LU1066051225.USD","IE00B543WZ88.USD","LU0980610538.SGD","LU0130517989.USD","IE00BLSP4239.USD","LU1093756168.USD","LU1035773651.USD","LU2125154778.USD","LU2125909247.SGD","LU0417516902.SGD","LU0511384066.AUD","LU1162221912.USD","IE00B2B36J28.USD","LU1934455277.USD","LU0861579265.USD","RXL","BK4550","LU0203347892.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU0432979614.USD","LU0124676726.USD","LU1571399168.USD","BMED","BK4585","LU1061106388.HKD","LU1989772840.SGD","IE00BSNM7G36.USD","LU1720050803.USD","IE00BPRC5H50.USD","LU0130102774.USD","LU0238689110.USD","LU1093756325.SGD","LU0868494617.USD","LU0868494708.USD","LU2125154935.USD","LU0289961442.SGD","LU0942090050.USD","SG9999001176.USD","LU0265550359.USD","PAWZ","IHE","IE0002141913.USD","LU0006306889.USD","LU0689626769.HKD","LU1923622614.USD","BK4516","LU0069063385.USD","LU0648001328.SGD","LU2361045086.USD","LU1585245621.USD","LU0965509010.AUD","LU1066051498.USD","LU0965509101.SGD","HRTS","LU0320765489.SGD","LU1941712264.USD","LU0348784397.USD","LU2023250504.SGD","LU0266013472.USD","LU1929549753.HKD","SG9999014559.SGD","LU2491050154.USD","LU0348767384.USD","BK4007","LU0106261372.USD","LU0417516738.SGD","LU0234572021.USD","LU0561508036.HKD","LU2491050071.SGD","SG9999014567.USD","LU1037948897.HKD","IXJ","LU0057025933.USD","LU1794554557.SGD","LU1983299246.USD","LU2361044949.HKD","LU0348766576.USD","IE000M9KFDE8.USD","LU2089984988.USD","LU1974910355.USD","LU0348827113.USD","LU2125909593.SGD","TRUH","JDOC","LU1066051811.HKD","LU2357627491.SGD","LU0320765646.SGD","SG9999015358.SGD","LU2491049909.HKD","LU1430594728.SGD","LU1201861249.SGD","IE00B1BXHZ80.USD","LU0211331839.USD","LU1291159041.SGD","LU2433249047.HKD","LU1917777945.USD","FTXH","LU0965509283.SGD","LU2468319806.SGD","LU2112291526.USD","LU0265550946.USD","IE00BJT1NW94.SGD","LU2324357040.USD","BK1574","LU1037948541.HKD","LU2106854487.HKD","BK1161","IE0009355771.USD","LU0985320562.USD","LU1057294990.SGD","LU0058720904.USD","LU1934455194.USD","SGXZ57979304.SGD","IYH","LU0289739699.SGD","LU0417516571.SGD","LU0203345920.USD","BK4534","LU2476274308.USD","LU0859254822.USD","LU1699723380.USD","BK4588","SG9999014575.USD","SG9999013999.USD","IE00B5MMRT66.SGD","SG9999015341.SGD","SG9999014542.SGD","LU1069347547.HKD","LU0540923850.HKD","IE00BN8TJ469.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610471","title":"恒瑞醫藥(600276.SH)：HRS-4139片獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610471","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667610471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:39","pubTimestamp":1789461583,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-4139片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-4139片是公司自主研发的1类新药，在动物模型中，可有效改善银屑病症状，抑制炎症反应。经查询，国内外暂无相同靶点药物获批上市。截至目前，HRS-4139片相关项目累计研发投入约2,040万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","IBBQ","LU1997244956.HKD","LU2097828631.EUR","BMED","LU1064131003.USD","LU1997245094.SGD","LU1655091616.SGD","MDTX","BK0028","LU1328615791.USD","LU2097828557.USD","LU2495084118.USD","LU0359202008.SGD","LU1023057109.AUD","LU2328871848.SGD","01276","LU1580142542.USD","BK0239","BK0188","LU1146622755.USD","LU2148510915.USD","LU2289578879.USD","LU2097828714.EUR","LU0359201612.USD","LU2097828805.USD","LU1255011170.USD","BK0183","LU1820825898.SGD","LU2488822045.USD","LU1969619763.USD","LU2543165471.USD","LU1997245177.USD","PSYK","IBBJ","LU1064130708.USD","LU0405327148.USD","LU0359201885.HKD","LU2580892789.USD","BK0012","LU0405327494.USD","600276","BK0196","LU2097828474.EUR","LU2580892862.HKD","LU1781817850.SGD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610193","title":"恒瑞醫藥：子公司HRS-4139片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667610193?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:35","pubTimestamp":1789461321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","PSYK","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667101906","title":"恒瑞醫藥：瑞卡西單抗獲批開展III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667101906","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667101906?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:35","pubTimestamp":1789461310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","BMED","IBBQ","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667832610","title":"維康藥業(300878.SZ)：黃甲軟肝顆粒獲批開展用於慢性乙型病毒性肝炎肝纖維化的III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667832610","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667832610?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:15","pubTimestamp":1789460131,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业(300878.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的黄甲软肝颗粒的《药物临床试验补充申请批准通知书》，经审查，黄甲软肝颗粒临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意开展用于慢性乙型病毒性肝炎肝纤维化的III期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","IBBJ","IBBQ","BK0239","300878","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661724","title":"維康藥業：黃甲軟肝顆粒獲III期臨床試驗補充申請批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661724?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:07","pubTimestamp":1789459662,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","IBBJ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617527","title":"興齊眼藥(300573.SZ)：SQ-25012注射液獲得臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617527","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617527?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 15:54","pubTimestamp":1789458841,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-25012注射液的《药物临床试验批准通知书》，同意本品开展拟用于治疗甲状腺眼病的临床试验。SQ-25012注射液是一款重组人源化IgG1型三特异性抗体，为公司研发的治疗用生物制品1类创新药，临床拟用于治疗甲状腺眼病。根据创新型治疗用生物制品1类注射剂的有关要求，公司已经完成SQ-25012注射液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-25012注射液具有良好的安全性及临床开发价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300573","IBBQ","MDTX","PSYK","BMED","BK0239","IBBJ","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617589","title":"興齊眼藥：SQ-25012注射液獲臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617589","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617589?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 15:51","pubTimestamp":1789458674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","BMED","PSYK","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667148376","title":"港股異動 | 海西新藥(02637)升逾3% 近期已遞交HX9428的DME IIa期新藥臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2667148376","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667148376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 14:48","pubTimestamp":1789454932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药涨超3%，截至发稿，涨2.89%，报195.5港元，成交额618.26万港元。消息面上，海西新药发布公告，本公司自主研发的创新药项目HXP056的候选药物分子HX9428，已于2026年8月31日正式向中国国家药品监督管理局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。公司表示，将继续全力推进HX9428在中美两地多项临床研究的进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","KCAI","02637","BK1191","BK4588","IBBJ","PSYK","IBBQ","MDTX","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194954760","title":"強生：瑞布侖特法斯普羅聯合拉茲克魯澤治療一年，因治療相關事件停藥率不足1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194954760","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194954760?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 11:03","pubTimestamp":1789441392,"startTime":"0","endTime":"0","summary":"强生公司披露了一项令人振奋的临床数据——在接受瑞布仑特法斯普罗（Rybrevant Faspro）与拉兹克鲁泽（Lazcluze）联合治疗方案的患者群体中，经过整整一年的治疗周期，因治疗相关不良事件而选择终止用药的比例，竟低于1%。这一数字无疑为这款联合疗法在临床实践中的耐受性写下了一份极具说服力的注脚。换言之，绝大多数患者不仅能够坚持完成长期治疗，而且在整个过程中所承受的药物相关副作用，鲜少达到需要中断治疗的严重程度。强生方面强调，这一低停药率数据，从耐受性维度为该联合方案提供了坚实的循证支持，也进一步巩固了其在相关适应症治疗格局中的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0001KFT4U8.USD","IE000M9KFDE8.USD","IE00BVYPNV92.GBP","IXJ","LU2756315664.SGD","LU1244550494.USD","IE000F7OJYX1.SGD","LU1718418525.SGD","IE00BFTCPJ56.SGD","LU2456880835.USD","LU1066051811.HKD","LU1032955483.USD","LU1023059063.AUD","LU0098860793.USD","LU0070217475.USD","IE00B19Z3581.USD","BK4550","JDOC","LU0069063385.USD","BK4568","LU2505996509.AUD","LU2896262040.SGD","IE0002270589.USD","LU1066051498.USD","LU2347655156.SGD","IE00BJT1NW94.SGD","LU2089984988.USD","LU1043141123.HKD","LU1914381329.SGD","SGXZ80539844.SGD","LU1244550577.SGD","LU0203347892.USD","LU1894683264.USD","IE000MB6IJN5.SGD","LU2471134952.CNY","IE00BN8TJ469.HKD","LU1267930813.SGD","LU0964807845.USD","LU1430594728.SGD","LU1221951046.USD","IE00BFXG1179.USD","LU1059921491.USD","IE00BSNM7G36.USD","RXL","LU2129689605.HKD","GDOC","LU0466842654.USD","BMED","LU0432979614.USD","IE00B3PB1722.GBP","LU0994945656.USD","IE00BZ1G4Q59.USD","LU0689626769.HKD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU2112291526.USD","VHT","LU0203345920.USD","LU1228905037.USD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0683600562.USD","BK4592","IHE","IYH","BK4504","LU1983299246.USD","BK4581","LU0057025933.USD","LU0289739343.SGD","LU2133065610.SGD","IE00BKVL7J92.USD","LU2213496289.HKD","BK4007","LU2430703251.USD","LU2750360641.GBP","LU1496350502.SGD","LU1551013342.USD","LU1989771016.USD","LU1291159041.SGD","SG9999001176.SGD","IE00BJJMRZ35.SGD","LU1629891620.HKD","LU0820562030.AUD","LU2471134796.USD","LU1066053197.SGD","LU0345770993.USD","IE00BLSP4452.SGD","LU2487616109.SGD","LU1196500208.SGD","LU0210536198.USD","LU2471134879.HKD","LU2129689431.USD","LU0795875169.SGD","LU0345769631.USD","LU1145028129.USD","LU0882574055.USD","LU1732799900.SGD","IE00BDGV0183.EUR","FHLC","MEDX","LU0426417589.USD","LU2750360997.AUD","LU2592432038.USD","LU0640476718.USD","IE00B2B36J28.USD","IE0000B7K699.USD","IE00BGHQF631.EUR","LU1074936037.SGD","SG9999001176.USD","LU0792757196.USD","LU2468319806.SGD","LU0889566641.SGD","LU0795875086.SGD","IE00BVYPNW00.USD","LU2602419157.SGD","LU0114720955.EUR","LU1261432733.SGD","TRUH","IE000WAW04H5.SGD","LU2403377893.USD","LU0210528500.USD","LU0345769128.USD","LU2129689514.USD","LU0162691827.USD","LU2505996681.GBP","LU2430703095.HKD","LU0124676726.USD","LU0426412945.USD","LU2236285917.USD","FTXH","LU0234570918.USD","BK4532","LU2756315318.SGD","SG9999002232.USD","IE00B1BXHZ80.USD","LU1280957306.USD","LU1732800096.USD","IE00B42XCP33.USD","LU1929549753.HKD","LU0912757837.SGD","IE00B3T34201.USD","IE00B7SZLL34.SGD","LU0234572021.USD","BK4534","LU0122379950.USD","LU0289739699.SGD","LU1221951129.SGD","BK4559","LU0787776722.HKD","LU1061106388.HKD","LU0689472784.USD","IE00BLSP4239.USD","IE0034235303.USD","LU0072461881.USD","LU1506573853.SGD","LU1674673691.USD","LU0320765646.SGD","LU1894683348.USD","XLV","LU0472753341.HKD","SG9999013999.USD","LU2417539215.USD","LU1162221912.USD","LU1032466523.USD","LU1551013425.SGD","LU2023250330.USD","PJP","LU0820561909.HKD","LU1778281490.HKD","SG9999001440.SGD","LU1244550221.USD","IE000SO60NU8.SGD","LU0345770308.USD","LU1674673428.USD","IE000BZT7R73.USD","LU0058720904.USD","LU1228905540.USD","LU0985320562.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU1121112475.USD","BK4533","IE0002141913.USD","LU0943347566.SGD","IE0009355771.USD","LU2430703178.SGD","LU0545562505.USD","BK4585","LU1043141396.HKD","SG9999002224.SGD","LU1066051225.USD","LU2471134523.USD","LU0820561818.USD","LU0053666078.USD","BK4588","JNJ","LU0511384066.AUD","LU1935042991.SGD","LU0289961442.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}